武田薬品工業
Takeda Pharmaceutical Co Ltd ADRUSUSDTakeda Pharmaceutical Co Ltd ADR (US:TKPHF) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 3. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la Empresa
- Sitio Web
- takeda.co.jp
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Central
- TOKYO, Japan
- Consejero Delegado
- Julie Kim
- Empleados
- 47 029
- Fundada
- 1781
- Acciones en Circulación
- Capital Flotante
- 3.16 mil M
- Capitalización Bursátil
- 10.08 B JPY
- Insiders
- 0.07%
- Inversores Institucionales
- 3.31%
- Industria (SIC)
- Pharmaceutical Preparations
- Forma Jurídica
- T417
- ISIN
- US8740602052
- LEI
- 549300ZLMVP4X0OGR454
- Ratio de Reparto
- pérdidas
- FCF
- 627 mil M JPY
- Pagos / FCF
- 49%
- Deuda
- 4.94 B JPY7.1 a. de FCF
- Racha de Dividendos
- —
- Beneficios, FCF y dividendos pagados — para los 12 meses hasta 30.06.2026 (el último informe de la compañía).
- NAV
Descripción
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Dividendos
Takeda Pharmaceutical Co Ltd ADR (TKPHF) paga dividendos dos veces al año. Por año (12 meses hasta e incluyendo el último pago anunciado): 202 JPY por acción (pagos: 2). Según el historial de pagos, se espera la próxima fecha ex-dividendo alrededor de 31.03.2027.
| Fecha Ex | Pago | Importe | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-09-30 | — | 102.0000 JPY | 1.7/3.5 % | semestral | US:TKPHF |
| 2026-03-31 | 2026-06-25 | 100.0000 JPY | 1.8/3.7 % | semestral | US:TKPHF |
| 2025-09-30 | 2025-12-01 | 100.0000 JPY | 2.2/4.3 % | semestral | US:TKPHF |
| 2025-03-31 | 2025-06-26 | 98.0000 JPY | 2.0/4.0 % | semestral | US:TKPHF |
| 2024-09-30 | 2024-12-02 | 98.0000 JPY | 2.4/≈4.7 % | semestral | US:TKPHF |
| 2024-03-28 | 2024-06-27 | 94.0000 JPY | 2.1/≈4.3 % | semestral | US:TKPHF |
Principales Accionistas
| Titular | Participación | Acciones | Fecha del Informe |
|---|---|---|---|
| Capital Research Global… | 0.6% | 19.3 M | 2026-06-30 |
| AMERICAN MUTUAL FUND | 0.57% | 18.16 M | 2026-06-30 |
| FMR, LLC | 0.3% | 9.6 M | 2026-06-30 |
| Morgan Stanley | 0.22% | 6.99 M | 2026-06-30 |
| Adage Capital Partners G… | 0.19% | 6.05 M | 2026-06-30 |
| Goldman Sachs Group Inc | 0.16% | 5.13 M | 2026-06-30 |
| Brandes Investment Partn… | 0.14% | 4.54 M | 2026-06-30 |
| Arrowstreet Capital, Lim… | 0.12% | 3.73 M | 2026-06-30 |
| Blackrock Inc. | 0.12% | 3.69 M | 2026-06-30 |
| Renaissance Technologies… | 0.08% | 2.57 M | 2026-06-30 |
| Qube Research & Technolo… | 0.07% | 2.21 M | 2026-06-30 |
| First TRT Exch-Trd Fd.-F… | 0.06% | 1.88 M | 2026-08-31 |
| VanEck ETF Trust-VanEck… | 0.06% | 1.79 M | 2026-08-31 |
| Steward Funds Inc-Stewar… | 0.02% | 711 871 | 2026-04-30 |
| Mercer Funds-Mercer Non-… | 0.02% | 586 098 | 2026-06-30 |
| American Century ETF Tru… | 0.02% | 553 008 | 2026-08-31 |
| GOLDMAN SACHS TRUST-Gold… | 0.02% | 494 442 | 2026-07-31 |
| WEBER CHRISTOPHE PIERRE… | ≈0.01% | 418 803 | 2026-04-27 |
| KIM JULIE SO-YOUNG (Chie… | ≈0.01% | 391 489 | 2026-08-10 |
| Trust for Professional M… | 0.01% | 170 113 | 2026-05-31 |
| MUTUAL FUND SERIES TRUST… | 0.01% | 169 000 | 2026-06-30 |
| PLATFORD GILES RICHARD (… | ≈0.01% | 315 838 | 2026-08-10 |
| BITETTI TERESA MARIE (Of… | ≈0.01% | 252 010 | 2026-08-10 |
| FURNEY NATALIE ANNE MARI… | ≈0.01% | 204 298 | 2026-08-10 |
| DUPREY LAUREN RUSCKOWSKI… | ≈0.01% | 191 522 | 2026-09-14 |
| PACHECO RHONDA JANICE (O… | ≈0.01% | 182 507 | 2026-08-10 |
| PIGNAGNOLI AGOSTI MARCEL… | ≈0.01% | 176 977 | 2026-08-10 |
| RICCI GABRIELE (Chief Te… | ≈0.01% | 171 654 | 2026-08-10 |
| Carillon Series Trust-Ca… | 0% | 160 000 | 2026-06-30 |
| PLUMP ANDREW STEWART (Of… | — | — | 2026-09-02 |
